The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
EHA 2024
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to myelofibrosis and polycythemia vera here.
CONGRESS | #EHA2024 | Claire Harrison @harrisoncn1 shares data from the phase II RESTORE trial of elritercept for the treatment of myelofibrosis and to mitigate ruxolitinib-associated cytopenias; concluding that elritercept was generally well tolerated with a RP2D selected of… pic.twitter.com/HPiO8MQsit
— MPN_Hub (@MPN_Hub) June 15, 2024
CONGRESS | #EHA2024 | @doctorpemm @MDAndersonNews presents efficacy and safety data from the phase III TRANSFORM-1 study of navitoclax plus ruxolitinib in previously untreated #myelofibrosis. In the nav+rux arm SVR35 was 63.2% vs 31.5% in the placebo+rux arm, TSS -9.7 vs -11.1,… pic.twitter.com/yoiQsjBjKs
— MPN_Hub (@MPN_Hub) June 15, 2024
CONGRESS | #EHA2024 | @RaajitRampal @MSKCancerCenter discusses the latest data from the phase III MANIFEST-2 trial of pelabresib with ruxolitinib for JAKi-naive #myelofibrosis. SVR35 65.9% vs 35.2% in RUX+placebo arm, loss of SVR35 13.4% vs 27.8%, dual SVR35/TSS50 40.2% vs 18.5%.… pic.twitter.com/FgjU1y9Suv
— MPN_Hub (@MPN_Hub) June 15, 2024
CONGRESS | #EHA2024 | @RaajitRampal @MSKCancerCenter shares preliminary evidence of bone marrow recovery from the MANIFEST-2 study of combination pelabresib-ruxolitinib JAK2 inhibitor-naïve #myelofibrosis. Pharmacodynamic markers indicate the potential for the combination to… pic.twitter.com/o4aEH85W4J
— MPN_Hub (@MPN_Hub) June 15, 2024
CONGRESS | POSTER | #ASCO24 | @DrJoeScandura presents the rationale, trial design, primary endpoints, and eligibility criteria for the phase II SENTRY-2 (XPORT-MF-044) clinical trial of selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia;… pic.twitter.com/OW8qLIGX3G
— MPN_Hub (@MPN_Hub) June 5, 2024
CONGRESS | POSTER | #ASCO24 | @sankalparoramd @MDAndersonNews shares the long term follow-up results of ruxolitinib in combination with azacitidine for the treatment of #myelofibrosis. An ORR rate of 74% was observed, median OS was 46 months, the most common higher grade AEs were… pic.twitter.com/6eEDCxx979
— MPN_Hub (@MPN_Hub) June 5, 2024
CONGRESS | POSTER | #ASCO24 | Ruben Mesa @mpdrc @WakeCancer shares the long-term survival, adjusted for treatment crossover, in pts with MF treated with momelotinib vs danazol from the MOMENTUM trial; concluding that long-term OS and LFS was observed in both arms, highlighting… pic.twitter.com/rKiLWZKLOh
— MPN_Hub (@MPN_Hub) June 4, 2024
CONGRESS | #ASCO24 | @RaajitRampal @MSKCancerCenter shares the updated safety and efficacy data from MANIFEST-2 of pelabresib + rux vs placebo + rux for JAKi-naïve myelofibrosis.
— MPN_Hub (@MPN_Hub) June 4, 2024
Loss of SVR35 13.4% vs 27.8%, SAEs 29.7% vs 29.4%, Grade ≥3 AE 49.1% vs 57%, anemia 44.8% vs 55.1%,… pic.twitter.com/CmMPOsxp9v
CONGRESS | #EHA2024 | @jjkiladjian @HopSaintLouis discusses the correlation between JAK2V617F molecular response and EFS in early #polycythemiavera. A 10% lower JAK2V617F allele burden was associated with a 34% decrease risk of events. Data also support the use of ropeginterferon… pic.twitter.com/TeWLaHfml7
— MPN_Hub (@MPN_Hub) June 15, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content